ACA
Acorn Capital Advisors Portfolio holdings
AUM
$153M
This Quarter Return
+3.01%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$153M
AUM Growth
+$2.95M
(+2%)
Cap. Flow
-$492K
Cap. Flow
% of AUM
-0.32%
Top 10 Holdings %
Top 10 Hldgs %
83.28%
Holding
22
New
–
Increased
7
Reduced
5
Closed
1
Top Buys
| 1 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
+$3.35M |
| 2 |
Candel Therapeutics
CADL
|
+$2.17M |
| 3 |
Protara Therapeutics
TARA
|
+$1.43M |
| 4 |
Y-mAbs Therapeutics
YMAB
|
+$828K |
| 5 |
Puma Biotechnology
PBYI
|
+$656K |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
+$3.88M |
| 2 |
UroGen Pharma
URGN
|
+$3.51M |
| 3 |
Mural Oncology
MURA
|
+$1.52M |
| 4 |
X4 Pharmaceuticals
XFOR
|
+$171K |
| 5 |
Cardiff Oncology
CRDF
|
+$106K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CG Oncology
CGON
$2.56B
| $29.4M | 19.24% |
1,131,501
| – | – |
|
|
2
UroGen Pharma
URGN
$884M
| $17.3M | 11.29% |
1,259,749
-256,554
| -17% | -$3.51M |
|
|
3
Y-mAbs Therapeutics
YMAB
$389M
| $15.4M | 10.09% |
3,418,995
+183,608
| +6% | +$828K |
|
|
4
Puma Biotechnology
PBYI
$228M
| $14.2M | 9.27% |
4,131,299
+191,247
| +5% | +$656K |
|
|
5
Candel Therapeutics
CADL
$267M
| $13.1M | 8.54% |
2,580,517
+428,265
| +20% | +$2.17M |
|
6
Trevi Therapeutics
TRVI
$1.17B
| $11.7M | 7.67% |
2,144,844
| – | – |
|
7
Terns Pharmaceuticals
TERN
$655M
| $7.35M | 4.81% |
1,971,264
| – | – |
|
|
OKUR
8
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$33.6M
| $6.79M | 4.44% |
2,839,674
+1,400,000
| +97% | +$3.35M |
|
|
CYBN
9
Cybin
CYBN
$148M
| $6.16M | 4.03% |
734,394
| – | – |
|
|
BCAX
10
Bicara Therapeutics Inc. Common Stock
BCAX
$650M
| $5.98M | 3.91% |
643,382
| – | – |
|
|
11
Protara Therapeutics
TARA
$120M
| $5.31M | 3.47% |
1,752,115
+472,315
| +37% | +$1.43M |
|
|
12
Cardiff Oncology
CRDF
$136M
| $4.44M | 2.9% |
1,408,767
-33,541
| -2% | -$106K |
|
13
Aura Biosciences
AURA
$400M
| $3.73M | 2.44% |
595,744
+5,236
| +0.9% | +$32.8K |
|
14
Verastem
VSTM
$608M
| $3.23M | 2.12% |
779,498
| – | – |
|
|
WHWK
15
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.4M
| $2.13M | 1.39% |
1,139,363
| – | – |
|
16
BioAtla
BCAB
$39.8M
| $1.91M | 1.25% |
4,835,111
+803,065
| +20% | +$318K |
|
|
17
Mural Oncology
MURA
$35.9M
| $1.61M | 1.06% |
653,779
-615,936
| -49% | -$1.52M |
|
18
VYNE Therapeutics
VYNE
$7.81M
| $1.22M | 0.79% |
736,572
-49,366
| -6% | -$81.5K |
|
19
Q32 Bio
QTTB
$21.6M
| $1.2M | 0.78% |
803,425
| – | – |
|
20
Acrivon Therapeutics
ACRV
$51.6M
| $482K | 0.32% |
405,237
| – | – |
|
|
21
X4 Pharmaceuticals
XFOR
$75.9M
| $292K | 0.19% |
153,730
-89,958
| -37% | -$171K |
|
|
OPTN
22
DELISTED
OptiNose
OPTN
| – | – |
-422,814
| Closed | -$3.88M |
|